New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
07:18 EDTCCXIChemoCentryx reports Q3 EPS (28c), consensus (22c)
Reports Q3 revenue $1.13M, consensus $4.75M
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:39 EDTCCXIChemoCentryx reports CCX507 well tolerated, effective in Phase I study
Subscribe for More Information
October 20, 2014
08:37 EDTCCXIChemoCentryx releases Phase III SHIELD 4 clinical results
ChemoCentryx reported data from the Phase III SHIELD 4 clinical trial in Crohn's disease with vercirnon, an inhibitor of the chemokine receptor known as CCR9. Data showed that patients experienced improved response and remission rates when taking a higher dose of vercirnon. There was no evidence of higher gastrointestinal, hepatic, or cardiovascular adverse events with the twice daily group compared to the once daily group. Thomas J. Schall, Ph.D., president and CEO stated, "These SHIELD 4 data are consistent with our earlier positive PROTECT-1 study data. As with PROTECT-1, the data indicate that vercirnon is safe and well tolerated in patients with Crohn's disease, and there is a dose-dependent improvement in symptoms in the observed patient population in SHIELD 4. The Phase III drug CCX282/vercirnon, in addition to our second-generation, Phase II-ready CCR9 inhibitor, CCX507, provide a strong complement of drugs in our CCR9 program for which we intend to find a strategic partner."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use